Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 2-3/2009

01.06.2009

Vascular Disease in Scleroderma

verfasst von: Fredrick M. Wigley

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2-3/2009

Einloggen, um Zugang zu erhalten

Abstract

Although scleroderma is generally considered a fibrosing disease of the tissues, it is now recognized that the underlying vascular disease is playing a fundamental role in its pathogenesis and associated tissue injury. The exact mechanism for the widespread scleroderma vascular disease is still unknown, but endothelial cell injury induced by infection, immune-mediated cytotoxicity, antiendothelial antibodies, and/or ischemia-reperfusion have all been implicated. The downstream effects of blood vessel perturbation produce “biomarkers” of vascular damage that reflect disease and may predict clinical outcomes. A complex interaction between endothelial cells, smooth muscle cells, extracellular matrix, and intravascular circulating factors is now recognized to contribute to the vascular reactivity, remodeling, and occlusive disease of scleroderma. Understanding the mechanisms underlying these processes provides rationale of novel therapeutic strategies and specific targeted therapy. This review will outline some of the evidence for the causes and consequences of scleroderma vascular disease.
Literatur
1.
Zurück zum Zitat Norton WL, Nardo JM (1970) Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73:317–324PubMed Norton WL, Nardo JM (1970) Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73:317–324PubMed
2.
Zurück zum Zitat LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22:675–694PubMedCrossRef LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22:675–694PubMedCrossRef
3.
Zurück zum Zitat Guiducci S, Giacomelli R, Cerinic MM (2007) Vascular complications of scleroderma. Autoimmun Rev 6:520–523PubMedCrossRef Guiducci S, Giacomelli R, Cerinic MM (2007) Vascular complications of scleroderma. Autoimmun Rev 6:520–523PubMedCrossRef
4.
Zurück zum Zitat Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum 52:1259–1263PubMedCrossRef Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum 52:1259–1263PubMedCrossRef
5.
Zurück zum Zitat Carpentier PH, Satger B, Poensin D, Maricq HR (2006) Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population. J Vasc Surg 44:1023–1028PubMedCrossRef Carpentier PH, Satger B, Poensin D, Maricq HR (2006) Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population. J Vasc Surg 44:1023–1028PubMedCrossRef
6.
Zurück zum Zitat Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993PubMedCrossRef Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993PubMedCrossRef
7.
Zurück zum Zitat Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837–3846PubMedCrossRef Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837–3846PubMedCrossRef
8.
Zurück zum Zitat Tiso F, Favaro M, Ciprian L, Cardarelli S, Rizzo M, Tonello M et al (2007) [Digital ulcers in a cohort of 333 scleroderma patients]. Reumatismo 59:215–220PubMed Tiso F, Favaro M, Ciprian L, Cardarelli S, Rizzo M, Tonello M et al (2007) [Digital ulcers in a cohort of 333 scleroderma patients]. Reumatismo 59:215–220PubMed
9.
Zurück zum Zitat Nihtyanova SI, Brough GM, Black CM, Denton CP (2008) Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67:120–123PubMedCrossRef Nihtyanova SI, Brough GM, Black CM, Denton CP (2008) Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67:120–123PubMedCrossRef
10.
Zurück zum Zitat Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V et al (2007) Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34:2423–2430PubMed Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V et al (2007) Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34:2423–2430PubMed
11.
Zurück zum Zitat Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693PubMedCrossRef Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693PubMedCrossRef
12.
Zurück zum Zitat Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326PubMedCrossRef Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326PubMedCrossRef
13.
Zurück zum Zitat Matucci-Cerinic M, Seibold JR (2008) Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v46–v47CrossRef Matucci-Cerinic M, Seibold JR (2008) Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v46–v47CrossRef
14.
Zurück zum Zitat Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39–43PubMedCrossRef Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39–43PubMedCrossRef
15.
Zurück zum Zitat Stucker M, Quinna S, Memmel U, Rochling A, Traupe M, Hoffmann K et al (2000) Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 5:295–302PubMed Stucker M, Quinna S, Memmel U, Rochling A, Traupe M, Hoffmann K et al (2000) Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 5:295–302PubMed
16.
Zurück zum Zitat Hasegawa M, Nagai Y, Tamura A, Ishikawa O (2006) Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 155:1159–1164PubMedCrossRef Hasegawa M, Nagai Y, Tamura A, Ishikawa O (2006) Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 155:1159–1164PubMedCrossRef
17.
Zurück zum Zitat Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393–408 Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393–408
18.
Zurück zum Zitat Youssef P, Englert H, Bertouch J (1993) Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 52:464–466PubMedCrossRef Youssef P, Englert H, Bertouch J (1993) Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 52:464–466PubMedCrossRef
19.
Zurück zum Zitat Stafford L, Englert H, Gover J, Bertouch J (1998) Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 57:476–479PubMedCrossRef Stafford L, Englert H, Gover J, Bertouch J (1998) Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 57:476–479PubMedCrossRef
20.
Zurück zum Zitat Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29:102–106PubMed Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29:102–106PubMed
21.
Zurück zum Zitat Constans J, Germain C, Gosse P, Taillard J, Tiev K, Delevaux I et al (2007) Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study. J Hypertens 25:1900–1906PubMedCrossRef Constans J, Germain C, Gosse P, Taillard J, Tiev K, Delevaux I et al (2007) Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study. J Hypertens 25:1900–1906PubMedCrossRef
22.
Zurück zum Zitat Hettema ME, Zhang D, Stienstra Y, Oomen PN, Smit AJ, Kallenberg CG et al (2008) Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. Rheumatology (Oxford) 47:1409–1412CrossRef Hettema ME, Zhang D, Stienstra Y, Oomen PN, Smit AJ, Kallenberg CG et al (2008) Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. Rheumatology (Oxford) 47:1409–1412CrossRef
23.
Zurück zum Zitat Sherer Y, Gerli R, Bocci EB, Gilburd B, Vaudo G, Bistoni O et al (2007) Heat-shock protein 65 autoantibodies are differently associated with early atherosclerosis in rheumatoid arthritis and in healthy subjects. Ann N Y Acad Sci 1108:408–413PubMedCrossRef Sherer Y, Gerli R, Bocci EB, Gilburd B, Vaudo G, Bistoni O et al (2007) Heat-shock protein 65 autoantibodies are differently associated with early atherosclerosis in rheumatoid arthritis and in healthy subjects. Ann N Y Acad Sci 1108:408–413PubMedCrossRef
24.
Zurück zum Zitat Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J et al (2007) Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) 46:772–775CrossRef Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J et al (2007) Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) 46:772–775CrossRef
25.
Zurück zum Zitat Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML et al (2007) Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 1108:283–290PubMedCrossRef Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML et al (2007) Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 1108:283–290PubMedCrossRef
26.
Zurück zum Zitat Szucs G, Timar O, Szekanecz Z, Der H, Kerekes G, Szamosi S et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762CrossRef Szucs G, Timar O, Szekanecz Z, Der H, Kerekes G, Szamosi S et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762CrossRef
27.
Zurück zum Zitat Bulkley BH, Roberts WC (1976) Atherosclerotic narrowing of the left main coronary artery. A necropsy analysis of 152 patients with fatal coronary heart disease and varying degrees of left main narrowing. Circulation 53:823–828PubMed Bulkley BH, Roberts WC (1976) Atherosclerotic narrowing of the left main coronary artery. A necropsy analysis of 152 patients with fatal coronary heart disease and varying degrees of left main narrowing. Circulation 53:823–828PubMed
28.
Zurück zum Zitat Bulkley BH, Klacsmann PG, Hutchins GM (1978) Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 95:563–569PubMedCrossRef Bulkley BH, Klacsmann PG, Hutchins GM (1978) Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 95:563–569PubMedCrossRef
29.
Zurück zum Zitat D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440PubMedCrossRef D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440PubMedCrossRef
30.
Zurück zum Zitat Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM et al (2006) Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 45:1395–1398CrossRef Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM et al (2006) Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 45:1395–1398CrossRef
31.
Zurück zum Zitat Maricq HR, Downey JA, LeRoy EC (1976) Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud’s syndrome. Blood Vessels 13:338–349PubMedCrossRef Maricq HR, Downey JA, LeRoy EC (1976) Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud’s syndrome. Blood Vessels 13:338–349PubMedCrossRef
32.
Zurück zum Zitat Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 16:619–628PubMedCrossRef Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 16:619–628PubMedCrossRef
33.
Zurück zum Zitat Maricq HR, Weinberger AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289–291PubMed Maricq HR, Weinberger AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289–291PubMed
34.
Zurück zum Zitat Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL (2005) Computerized nailfold video capillaroscopy—a new tool for assessment of Raynaud’s phenomenon. J Rheumatol 32:841–848PubMed Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL (2005) Computerized nailfold video capillaroscopy—a new tool for assessment of Raynaud’s phenomenon. J Rheumatol 32:841–848PubMed
35.
Zurück zum Zitat Wildt M, Hesselstrand R, Akesson A, Scheja A (2007) Simple counting of nailfold capillary density in suspected systemic sclerosis—9 years’ experience. Scand J Rheumatol 36:452–457PubMedCrossRef Wildt M, Hesselstrand R, Akesson A, Scheja A (2007) Simple counting of nailfold capillary density in suspected systemic sclerosis—9 years’ experience. Scand J Rheumatol 36:452–457PubMedCrossRef
36.
Zurück zum Zitat Maricq HR, LeRoy EC, D’Angelo WA, Medsger TA Jr, Rodnan GP, Sharp GC et al (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23:183–189PubMedCrossRef Maricq HR, LeRoy EC, D’Angelo WA, Medsger TA Jr, Rodnan GP, Sharp GC et al (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23:183–189PubMedCrossRef
37.
Zurück zum Zitat Cutolo M, Pizzorni C, Sulli A (2004) Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol 63:457–462PubMedCrossRef Cutolo M, Pizzorni C, Sulli A (2004) Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol 63:457–462PubMedCrossRef
38.
Zurück zum Zitat Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC (1982) A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 72:883–888PubMedCrossRef Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC (1982) A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 72:883–888PubMedCrossRef
39.
Zurück zum Zitat Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC (1983) Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1:195–205PubMed Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC (1983) Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1:195–205PubMed
40.
Zurück zum Zitat Houtman PM, Kallenberg CG, Fidler V, Wouda AA (1986) Diagnostic significance of nailfold capillary patterns in patients with Raynaud’s phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 13:556–563PubMed Houtman PM, Kallenberg CG, Fidler V, Wouda AA (1986) Diagnostic significance of nailfold capillary patterns in patients with Raynaud’s phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 13:556–563PubMed
41.
Zurück zum Zitat ter Borg EJ, Piersma-Wichers G, Smit AJ, Kallenberg CG, Wouda AA (1994) Serial nailfold capillary microscopy in primary Raynaud’s phenomenon and scleroderma. Semin Arthritis Rheum 24:40–47PubMedCrossRef ter Borg EJ, Piersma-Wichers G, Smit AJ, Kallenberg CG, Wouda AA (1994) Serial nailfold capillary microscopy in primary Raynaud’s phenomenon and scleroderma. Semin Arthritis Rheum 24:40–47PubMedCrossRef
42.
Zurück zum Zitat Meli M, Gitzelmann G, Koppensteiner R, mann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158PubMedCrossRef Meli M, Gitzelmann G, Koppensteiner R, mann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158PubMedCrossRef
43.
Zurück zum Zitat Sulli A, Secchi ME, Pizzorni C, Cutolo M (2008) Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 67:885–887PubMedCrossRef Sulli A, Secchi ME, Pizzorni C, Cutolo M (2008) Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 67:885–887PubMedCrossRef
44.
45.
Zurück zum Zitat Di FM, Paradiso M, Riccieri V, Basili S, Mammarella A, Valesini G (2007) Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 26:1278–1283CrossRef Di FM, Paradiso M, Riccieri V, Basili S, Mammarella A, Valesini G (2007) Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 26:1278–1283CrossRef
46.
Zurück zum Zitat Braverman IM, Ken-Yen A (1983) Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 81:489–497PubMedCrossRef Braverman IM, Ken-Yen A (1983) Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 81:489–497PubMedCrossRef
47.
Zurück zum Zitat Walker JG, Stirling J, Beroukas D, Dharmapatni K, Haynes DR, Smith MD et al (2005) Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology 37:220–225PubMedCrossRef Walker JG, Stirling J, Beroukas D, Dharmapatni K, Haynes DR, Smith MD et al (2005) Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology 37:220–225PubMedCrossRef
48.
Zurück zum Zitat Kazandjian S, Bruneval P, Fiessinger JN, Camilleri JP, Housset E (1986) Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch Dermatol Res 279:8–11PubMedCrossRef Kazandjian S, Bruneval P, Fiessinger JN, Camilleri JP, Housset E (1986) Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch Dermatol Res 279:8–11PubMedCrossRef
49.
Zurück zum Zitat Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome). Am J Med Genet 91:66–67PubMedCrossRef Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome). Am J Med Genet 91:66–67PubMedCrossRef
50.
Zurück zum Zitat Mould TL, Roberts-Thomson PJ (2000) Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 18:195–200PubMed Mould TL, Roberts-Thomson PJ (2000) Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 18:195–200PubMed
51.
Zurück zum Zitat McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345–351PubMedCrossRef McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345–351PubMedCrossRef
52.
Zurück zum Zitat Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189–195PubMedCrossRef Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189–195PubMedCrossRef
53.
Zurück zum Zitat Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K et al (2006) A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 213:88–92PubMedCrossRef Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K et al (2006) A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 213:88–92PubMedCrossRef
54.
Zurück zum Zitat Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O et al (2007) Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46:622–625CrossRef Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O et al (2007) Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46:622–625CrossRef
55.
Zurück zum Zitat Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A et al (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 47:972–975CrossRef Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A et al (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 47:972–975CrossRef
56.
Zurück zum Zitat Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, Kumar S et al (2001) The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 19:275–282PubMed Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, Kumar S et al (2001) The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 19:275–282PubMed
57.
Zurück zum Zitat Coffman JD, Cohen AS (1971) Total and capillary fingertip blood flow in Raynaud’s phenomenon. N Engl J Med 285:259–263PubMed Coffman JD, Cohen AS (1971) Total and capillary fingertip blood flow in Raynaud’s phenomenon. N Engl J Med 285:259–263PubMed
58.
Zurück zum Zitat Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr, Steen VD et al (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62:335–352 Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr, Steen VD et al (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62:335–352
59.
Zurück zum Zitat Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 53:1–46CrossRef Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 53:1–46CrossRef
60.
Zurück zum Zitat Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485–494PubMedCrossRef Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485–494PubMedCrossRef
61.
Zurück zum Zitat Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR et al (1984) Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 310:142–148PubMed Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR et al (1984) Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 310:142–148PubMed
62.
Zurück zum Zitat Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN Jr et al (1986) Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 105:661–668PubMed Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN Jr et al (1986) Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 105:661–668PubMed
63.
64.
Zurück zum Zitat Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944PubMedCrossRef Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944PubMedCrossRef
65.
Zurück zum Zitat Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282PubMedCrossRef Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282PubMedCrossRef
66.
Zurück zum Zitat Sallam H, McNearney TA, Chen JD (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23:691–712PubMedCrossRef Sallam H, McNearney TA, Chen JD (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23:691–712PubMedCrossRef
67.
Zurück zum Zitat Nehra A, Hall SJ, Basile G, Bertero EB, Moreland R, Toselli P et al (1995) Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153:1140–1146PubMedCrossRef Nehra A, Hall SJ, Basile G, Bertero EB, Moreland R, Toselli P et al (1995) Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153:1140–1146PubMedCrossRef
68.
Zurück zum Zitat Lewis T (2008) The pathological changes in the arteries supplying the fingers in warm-handed people and in cases of so called Raynaud’s disease. Clin Sci (Lond) 3:287–319 Lewis T (2008) The pathological changes in the arteries supplying the fingers in warm-handed people and in cases of so called Raynaud’s disease. Clin Sci (Lond) 3:287–319
69.
Zurück zum Zitat Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393–400PubMedCrossRef Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393–400PubMedCrossRef
70.
Zurück zum Zitat Salerni R, Rodnan GP, Leon DF, Shaver JA (1977) Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86:394–399PubMed Salerni R, Rodnan GP, Leon DF, Shaver JA (1977) Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86:394–399PubMed
71.
Zurück zum Zitat Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515–524PubMedCrossRef Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515–524PubMedCrossRef
72.
Zurück zum Zitat Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD et al (1989) Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038–1042PubMed Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD et al (1989) Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038–1042PubMed
73.
Zurück zum Zitat Yousem SA (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21:467–474PubMedCrossRef Yousem SA (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21:467–474PubMedCrossRef
74.
Zurück zum Zitat Nagai Y, Yamanaka M, Hashimoto C, Nakano A, Hasegawa A, Tanaka Y et al (2007) Autopsy case of systemic sclerosis with severe pulmonary hypertension. J Dermatol 34:769–772PubMedCrossRef Nagai Y, Yamanaka M, Hashimoto C, Nakano A, Hasegawa A, Tanaka Y et al (2007) Autopsy case of systemic sclerosis with severe pulmonary hypertension. J Dermatol 34:769–772PubMedCrossRef
75.
Zurück zum Zitat Cool CD, Kennedy D, Voelkel NF, Tuder RM (1997) Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434–442PubMedCrossRef Cool CD, Kennedy D, Voelkel NF, Tuder RM (1997) Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434–442PubMedCrossRef
76.
Zurück zum Zitat Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703PubMedCrossRef Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703PubMedCrossRef
77.
Zurück zum Zitat Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidine. Arch Dermatol 112:1553–1557PubMedCrossRef Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidine. Arch Dermatol 112:1553–1557PubMedCrossRef
78.
Zurück zum Zitat Trotta F, Biagini G, Cenacchi G, Ballardini G, Varotti C, Passarini B et al (1984) Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 2:209–215PubMed Trotta F, Biagini G, Cenacchi G, Ballardini G, Varotti C, Passarini B et al (1984) Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 2:209–215PubMed
79.
Zurück zum Zitat Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263PubMedCrossRef Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263PubMedCrossRef
80.
Zurück zum Zitat Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126:561–568PubMedCrossRef Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126:561–568PubMedCrossRef
81.
Zurück zum Zitat Fleischmajer R, Perlish JS (1977) [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 69:379–382PubMedCrossRef Fleischmajer R, Perlish JS (1977) [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 69:379–382PubMedCrossRef
82.
Zurück zum Zitat Kazandjian S, Fiessinger JN, Camilleri JP, Dadoune JP, Housset E (1982) Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 62:425–429PubMed Kazandjian S, Fiessinger JN, Camilleri JP, Dadoune JP, Housset E (1982) Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 62:425–429PubMed
83.
Zurück zum Zitat Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161–170PubMed Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161–170PubMed
84.
Zurück zum Zitat Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3:e1452PubMedCrossRef Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3:e1452PubMedCrossRef
85.
Zurück zum Zitat Hummers LK (2008) Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v21–v22CrossRef Hummers LK (2008) Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v21–v22CrossRef
86.
Zurück zum Zitat Kahaleh MB, Osborn I, LeRoy EC (1981) Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud’s phenomenon. Ann Intern Med 94:482–484PubMed Kahaleh MB, Osborn I, LeRoy EC (1981) Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud’s phenomenon. Ann Intern Med 94:482–484PubMed
87.
Zurück zum Zitat James JP, Stevens TR, Hall ND, Maddison PJ, Goulding NJ, Silman A et al (1990) Factor VIII related antigen in connective tissue disease patients and relatives. Br J Rheumatol 29:6–9PubMedCrossRef James JP, Stevens TR, Hall ND, Maddison PJ, Goulding NJ, Silman A et al (1990) Factor VIII related antigen in connective tissue disease patients and relatives. Br J Rheumatol 29:6–9PubMedCrossRef
88.
Zurück zum Zitat Herrick AL, Barlow JD, Bowden A, Williams N, Hobson AR, Irving M et al (1996) Investigation of anal function in patients with systemic sclerosis. Ann Rheum Dis 55:370–374PubMedCrossRef Herrick AL, Barlow JD, Bowden A, Williams N, Hobson AR, Irving M et al (1996) Investigation of anal function in patients with systemic sclerosis. Ann Rheum Dis 55:370–374PubMedCrossRef
89.
Zurück zum Zitat Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A (1992) Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud’s phenomenon. Int J Microcirc Clin Exp 11:375–382PubMed Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A (1992) Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud’s phenomenon. Int J Microcirc Clin Exp 11:375–382PubMed
90.
Zurück zum Zitat Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D et al (2003) Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 22:196–202PubMedCrossRef Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D et al (2003) Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 22:196–202PubMedCrossRef
91.
Zurück zum Zitat Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenon. J Rheumatol 20:1325–1330PubMed Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenon. J Rheumatol 20:1325–1330PubMed
92.
Zurück zum Zitat Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S2PubMedCrossRef Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S2PubMedCrossRef
93.
Zurück zum Zitat Silver RM (2008) Endothelin and scleroderma lung disease. Rheumatology (Oxford) 47(Suppl 5):v25–v26CrossRef Silver RM (2008) Endothelin and scleroderma lung disease. Rheumatology (Oxford) 47(Suppl 5):v25–v26CrossRef
94.
Zurück zum Zitat Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34:978–983PubMedCrossRef Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34:978–983PubMedCrossRef
95.
Zurück zum Zitat Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H et al (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566–1571PubMed Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H et al (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566–1571PubMed
96.
Zurück zum Zitat Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC (1993) Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 69:199–204PubMedCrossRef Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC (1993) Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 69:199–204PubMedCrossRef
97.
Zurück zum Zitat Yamane K (1994) Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med 33:579–582PubMedCrossRef Yamane K (1994) Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med 33:579–582PubMedCrossRef
98.
Zurück zum Zitat Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMed Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMed
99.
Zurück zum Zitat Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K (1995) Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 287:439–442PubMedCrossRef Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K (1995) Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 287:439–442PubMedCrossRef
100.
Zurück zum Zitat Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM et al (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34:1048–1054PubMedCrossRef Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM et al (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34:1048–1054PubMedCrossRef
101.
Zurück zum Zitat Tabata H, Yamakage A, Yamazaki S (1997) Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 36:272–275PubMedCrossRef Tabata H, Yamakage A, Yamazaki S (1997) Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 36:272–275PubMedCrossRef
102.
Zurück zum Zitat Silveri F, De AR, Poggi A, Muti S, Bonapace G, Argentati F et al (2001) Relative roles of endothelial cell damage and platelet activation in primary Raynaud’s phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 30:290–296PubMedCrossRef Silveri F, De AR, Poggi A, Muti S, Bonapace G, Argentati F et al (2001) Relative roles of endothelial cell damage and platelet activation in primary Raynaud’s phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 30:290–296PubMedCrossRef
103.
Zurück zum Zitat Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–579PubMedCrossRef Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–579PubMedCrossRef
104.
Zurück zum Zitat Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 96:610–613PubMed Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 96:610–613PubMed
105.
Zurück zum Zitat Kahaleh MB, Scharstein KK, LeRoy EC (1985) Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets. J Rheumatol 12:468–471PubMed Kahaleh MB, Scharstein KK, LeRoy EC (1985) Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets. J Rheumatol 12:468–471PubMed
106.
Zurück zum Zitat Lima J, Fonollosa V, Fernandez-Cortijo J, Ordi J, Cuenca R, Khamashta MA et al (1991) Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 18:1833–1836PubMed Lima J, Fonollosa V, Fernandez-Cortijo J, Ordi J, Cuenca R, Khamashta MA et al (1991) Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 18:1833–1836PubMed
107.
Zurück zum Zitat Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM et al (2002) Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 29:2565–2570PubMed Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM et al (2002) Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 29:2565–2570PubMed
108.
Zurück zum Zitat Reilly IA, Roy L, Fitzgerald GA (1986) Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud’s phenomenon. Br Med J (Clin Res Ed) 292:1037–1039 Reilly IA, Roy L, Fitzgerald GA (1986) Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud’s phenomenon. Br Med J (Clin Res Ed) 292:1037–1039
109.
Zurück zum Zitat Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N (2007) Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 18:297–302PubMedCrossRef Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N (2007) Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 18:297–302PubMedCrossRef
110.
Zurück zum Zitat Guiducci S, Distler JH, Jungel A, Huscher D, Huber LC, Michel BA et al (2008) The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 58:2845–2853PubMedCrossRef Guiducci S, Distler JH, Jungel A, Huscher D, Huber LC, Michel BA et al (2008) The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 58:2845–2853PubMedCrossRef
111.
Zurück zum Zitat Gruschwitz M, von den DP, Kellner I, Hornstein OP, Sterry W (1992) Expression of adhesion proteins involved in cell–cell and cell–matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 27:169–177PubMedCrossRef Gruschwitz M, von den DP, Kellner I, Hornstein OP, Sterry W (1992) Expression of adhesion proteins involved in cell–cell and cell–matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 27:169–177PubMedCrossRef
112.
Zurück zum Zitat Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HW et al (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 97:667–671PubMedCrossRef Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HW et al (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 97:667–671PubMedCrossRef
113.
Zurück zum Zitat Kraling BM, Jimenez SA, Sorger T, Maul GG (1994) Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 71:745–754PubMed Kraling BM, Jimenez SA, Sorger T, Maul GG (1994) Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 71:745–754PubMed
114.
Zurück zum Zitat Sollberg S, Peltonen J, Uitto J, Jimenez SA (1992) Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290–298PubMedCrossRef Sollberg S, Peltonen J, Uitto J, Jimenez SA (1992) Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290–298PubMedCrossRef
115.
Zurück zum Zitat Gruschwitz MS, Hornstein OP, von den DP (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184–189PubMedCrossRef Gruschwitz MS, Hornstein OP, von den DP (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184–189PubMedCrossRef
116.
Zurück zum Zitat Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W (1993) Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 20:809–814PubMed Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W (1993) Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 20:809–814PubMed
117.
Zurück zum Zitat Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B (1998) Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 37:304–310PubMedCrossRef Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B (1998) Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 37:304–310PubMedCrossRef
118.
Zurück zum Zitat Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K et al (1997) Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270–1275PubMedCrossRef Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K et al (1997) Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270–1275PubMedCrossRef
119.
Zurück zum Zitat Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487PubMed Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487PubMed
120.
Zurück zum Zitat Veale DJ, Kirk G, McLaren M, Belch JJ (1998) Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 37:1227–1228PubMedCrossRef Veale DJ, Kirk G, McLaren M, Belch JJ (1998) Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 37:1227–1228PubMedCrossRef
121.
Zurück zum Zitat Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192PubMedCrossRef Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192PubMedCrossRef
122.
Zurück zum Zitat Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2006) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319PubMedCrossRef Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2006) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319PubMedCrossRef
123.
Zurück zum Zitat Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ et al (1998) Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 91:561–566PubMedCrossRef Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ et al (1998) Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 91:561–566PubMedCrossRef
124.
Zurück zum Zitat Mulligan-Kehoe MJ, Simons M (2007) Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 9:173–179PubMedCrossRef Mulligan-Kehoe MJ, Simons M (2007) Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 9:173–179PubMedCrossRef
125.
Zurück zum Zitat Mulligan-Kehoe MJ, Simons M (2008) Vascular disease in scleroderma: angiogenesis and vascular repair. Rheum Dis Clin North Am 34:73–79PubMedCrossRef Mulligan-Kehoe MJ, Simons M (2008) Vascular disease in scleroderma: angiogenesis and vascular repair. Rheum Dis Clin North Am 34:73–79PubMedCrossRef
126.
Zurück zum Zitat Kahaleh MB, Sherer GK, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326–1335PubMedCrossRef Kahaleh MB, Sherer GK, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326–1335PubMedCrossRef
127.
Zurück zum Zitat Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A et al (2007) Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56:3448–3458PubMedCrossRef Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A et al (2007) Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56:3448–3458PubMedCrossRef
128.
Zurück zum Zitat Marczak M, Majewski S, Skopinska-Rozewska E, Polakowski I, Jablonska S (1986) Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. J Invest Dermatol 86:355–358PubMedCrossRef Marczak M, Majewski S, Skopinska-Rozewska E, Polakowski I, Jablonska S (1986) Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. J Invest Dermatol 86:355–358PubMedCrossRef
129.
Zurück zum Zitat Kahaleh MB, DeLustro F, Bock W, LeRoy EC (1986) Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol 39:242–255PubMedCrossRef Kahaleh MB, DeLustro F, Bock W, LeRoy EC (1986) Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol 39:242–255PubMedCrossRef
130.
Zurück zum Zitat Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3PubMedCrossRef Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3PubMedCrossRef
131.
Zurück zum Zitat Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F et al (2006) A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 8:R115PubMedCrossRef Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F et al (2006) A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 8:R115PubMedCrossRef
132.
Zurück zum Zitat Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef
133.
Zurück zum Zitat Ribatti D, Cantatore FP, Vacca A, D’Amore M, Ria R, Roncali L et al (1998) Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin Rheumatol 17:115–120PubMedCrossRef Ribatti D, Cantatore FP, Vacca A, D’Amore M, Ria R, Roncali L et al (1998) Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin Rheumatol 17:115–120PubMedCrossRef
134.
Zurück zum Zitat Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11PubMedCrossRef Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11PubMedCrossRef
135.
Zurück zum Zitat Davies CA, Jeziorska M, Freemont AJ, Herrick AL (2006) The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37:190–197PubMedCrossRef Davies CA, Jeziorska M, Freemont AJ, Herrick AL (2006) The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37:190–197PubMedCrossRef
136.
Zurück zum Zitat Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116PubMedCrossRef Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116PubMedCrossRef
137.
Zurück zum Zitat Qazi U, Lam C, Karumanchi SA, Petri M (2008) Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 35:631–634PubMed Qazi U, Lam C, Karumanchi SA, Petri M (2008) Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 35:631–634PubMed
138.
Zurück zum Zitat Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889–893PubMedCrossRef Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889–893PubMedCrossRef
139.
Zurück zum Zitat Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, de Graft-Johnson JE, Zalewska A, Luczynska M et al (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis—association with pulmonary involvement. Clin Exp Rheumatol 24:508–513PubMed Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, de Graft-Johnson JE, Zalewska A, Luczynska M et al (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis—association with pulmonary involvement. Clin Exp Rheumatol 24:508–513PubMed
140.
Zurück zum Zitat Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A (2005) Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005:144–149PubMedCrossRef Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A (2005) Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005:144–149PubMedCrossRef
141.
Zurück zum Zitat Hummers LK, Hall A, Wigley F, Simons M (2004) Evidence for abnormal angiogenesis in scleroderma patients. Arthritis Rheum 50:S630 Hummers LK, Hall A, Wigley F, Simons M (2004) Evidence for abnormal angiogenesis in scleroderma patients. Arthritis Rheum 50:S630
142.
Zurück zum Zitat D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del RA, Margheri F et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275–3285PubMedCrossRef D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del RA, Margheri F et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275–3285PubMedCrossRef
143.
Zurück zum Zitat Del RA, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S et al (2005) Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 64:382–387 Del RA, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S et al (2005) Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 64:382–387
144.
Zurück zum Zitat Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F et al (2005) The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 52:3618–3628PubMedCrossRef Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F et al (2005) The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 52:3618–3628PubMedCrossRef
145.
Zurück zum Zitat Distler JH, Gay S, Distler O (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii26–iii27CrossRef Distler JH, Gay S, Distler O (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii26–iii27CrossRef
146.
Zurück zum Zitat Gomer RH (2008) Circulating progenitor cells and scleroderma. Curr Rheumatol Rep 10:183–188PubMedCrossRef Gomer RH (2008) Circulating progenitor cells and scleroderma. Curr Rheumatol Rep 10:183–188PubMedCrossRef
147.
Zurück zum Zitat Del PN, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W et al (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50:1296–1304CrossRef Del PN, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W et al (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50:1296–1304CrossRef
148.
Zurück zum Zitat Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25:60–66PubMed Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25:60–66PubMed
149.
Zurück zum Zitat Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610PubMedCrossRef Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610PubMedCrossRef
150.
Zurück zum Zitat Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615PubMedCrossRef Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615PubMedCrossRef
151.
Zurück zum Zitat Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004PubMedCrossRef Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004PubMedCrossRef
152.
Zurück zum Zitat Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54:1946–1951PubMedCrossRef Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54:1946–1951PubMedCrossRef
153.
Zurück zum Zitat Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T (2006) Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 65:1118–1120PubMedCrossRef Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T (2006) Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 65:1118–1120PubMedCrossRef
154.
155.
Zurück zum Zitat Derk CT, Jimenez SA (2006) Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 5:25–32PubMedCrossRef Derk CT, Jimenez SA (2006) Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 5:25–32PubMedCrossRef
156.
Zurück zum Zitat Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35:1801–1808PubMed Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35:1801–1808PubMed
157.
Zurück zum Zitat Freedman RR, Girgis R, Mayes MD (1999) Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. J Rheumatol 26:2386–2388PubMed Freedman RR, Girgis R, Mayes MD (1999) Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. J Rheumatol 26:2386–2388PubMed
158.
Zurück zum Zitat Freedman RR, Girgis R, Mayes MD (2001) Abnormal responses to endothelial agonists in Raynaud’s phenomenon and scleroderma. J Rheumatol 28:119–121PubMed Freedman RR, Girgis R, Mayes MD (2001) Abnormal responses to endothelial agonists in Raynaud’s phenomenon and scleroderma. J Rheumatol 28:119–121PubMed
159.
Zurück zum Zitat Freedman RR, Girgis R, Mayes MD (1999) Acute effect of nitric oxide on Raynaud’s phenomenon in scleroderma. Lancet 354:739PubMedCrossRef Freedman RR, Girgis R, Mayes MD (1999) Acute effect of nitric oxide on Raynaud’s phenomenon in scleroderma. Lancet 354:739PubMedCrossRef
160.
Zurück zum Zitat Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 43:1085–1093PubMedCrossRef Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 43:1085–1093PubMedCrossRef
161.
Zurück zum Zitat Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273–278PubMedCrossRef Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273–278PubMedCrossRef
162.
Zurück zum Zitat Yamamoto T, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25:314–317PubMed Yamamoto T, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25:314–317PubMed
163.
Zurück zum Zitat Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M et al (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45:676–684CrossRef Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M et al (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45:676–684CrossRef
164.
Zurück zum Zitat Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM et al (2008) Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol 27:315–322PubMedCrossRef Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM et al (2008) Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol 27:315–322PubMedCrossRef
165.
Zurück zum Zitat Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R et al (2000) Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 5:147–158PubMed Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R et al (2000) Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 5:147–158PubMed
166.
Zurück zum Zitat Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051–1055PubMed Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051–1055PubMed
167.
Zurück zum Zitat Fajac I, Kahan A, Menkes CJ, Dessanges JF, l’Ava-Santucci J, nh-Xuan AT (1998) Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 16:547–552PubMed Fajac I, Kahan A, Menkes CJ, Dessanges JF, l’Ava-Santucci J, nh-Xuan AT (1998) Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 16:547–552PubMed
168.
Zurück zum Zitat Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ (1999) Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115:1352–1356PubMedCrossRef Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ (1999) Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115:1352–1356PubMedCrossRef
169.
Zurück zum Zitat Shimizu K, Ogawa F, Muroi E, Hara T, Komura K, Bae SJ et al (2007) Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. Clin Exp Rheumatol 25:281–286PubMed Shimizu K, Ogawa F, Muroi E, Hara T, Komura K, Bae SJ et al (2007) Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. Clin Exp Rheumatol 25:281–286PubMed
170.
Zurück zum Zitat Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150PubMedCrossRef Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150PubMedCrossRef
171.
Zurück zum Zitat Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM (1995) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060–1067PubMedCrossRef Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM (1995) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060–1067PubMedCrossRef
172.
Zurück zum Zitat Herrick AL, Matucci CM (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4–8PubMed Herrick AL, Matucci CM (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4–8PubMed
173.
Zurück zum Zitat Ruiz-Ortega M, Ruperez M, Esteban V, Egido J (2003) Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5:73–79PubMedCrossRef Ruiz-Ortega M, Ruperez M, Esteban V, Egido J (2003) Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5:73–79PubMedCrossRef
174.
Zurück zum Zitat Cohn RD, van EC, Habashi JP, Soleimani AA, Klein EC, Lisi MT et al (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13:204–210PubMedCrossRef Cohn RD, van EC, Habashi JP, Soleimani AA, Klein EC, Lisi MT et al (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13:204–210PubMedCrossRef
175.
Zurück zum Zitat Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358:2787–2795PubMedCrossRef Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358:2787–2795PubMedCrossRef
176.
Zurück zum Zitat Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111:2509–2517PubMedCrossRef Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111:2509–2517PubMedCrossRef
177.
Zurück zum Zitat Orfanos SE, Psevdi E, Stratigis N, Langleben D, Catravas JD, Kyriakidis M et al (2001) Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 44:902–911PubMedCrossRef Orfanos SE, Psevdi E, Stratigis N, Langleben D, Catravas JD, Kyriakidis M et al (2001) Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 44:902–911PubMedCrossRef
178.
Zurück zum Zitat Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senecal JL et al (2008) Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum 58:1156–1164PubMedCrossRef Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senecal JL et al (2008) Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum 58:1156–1164PubMedCrossRef
179.
Zurück zum Zitat Fatini C, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML et al (2002) High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 112:540–544PubMedCrossRef Fatini C, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML et al (2002) High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 112:540–544PubMedCrossRef
180.
Zurück zum Zitat Pignone A, Rosso AD, Brosnihan KB, Perfetto F, Livi R, Fiori G et al (2007) Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 66:1305–1310PubMedCrossRef Pignone A, Rosso AD, Brosnihan KB, Perfetto F, Livi R, Fiori G et al (2007) Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 66:1305–1310PubMedCrossRef
181.
182.
Zurück zum Zitat Murray AK, Moore TL, King TA, Herrick AL (2006) Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum 54:1952–1960PubMedCrossRef Murray AK, Moore TL, King TA, Herrick AL (2006) Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum 54:1952–1960PubMedCrossRef
183.
Zurück zum Zitat Albrecht HP, Hiller D, Hornstein OP, Buhler-Singer S, Muck M, Gruschwitz M (1993) Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol 101:211–215PubMedCrossRef Albrecht HP, Hiller D, Hornstein OP, Buhler-Singer S, Muck M, Gruschwitz M (1993) Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol 101:211–215PubMedCrossRef
184.
Zurück zum Zitat Roustit M, Simmons GH, Carpentier P, Cracowski JL (2008) Abnormal digital neurovascular response to local heating in systemic sclerosis. Rheumatology (Oxford) 47:860–864CrossRef Roustit M, Simmons GH, Carpentier P, Cracowski JL (2008) Abnormal digital neurovascular response to local heating in systemic sclerosis. Rheumatology (Oxford) 47:860–864CrossRef
185.
Zurück zum Zitat Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I et al (1998) Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J 136:905–912PubMedCrossRef Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I et al (1998) Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J 136:905–912PubMedCrossRef
186.
Zurück zum Zitat Khan F, Belch JJ (1999) Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral l-arginine supplementation. J Rheumatol 26:2389–2394PubMed Khan F, Belch JJ (1999) Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral l-arginine supplementation. J Rheumatol 26:2389–2394PubMed
187.
Zurück zum Zitat Gunawardena H, Harris ND, Carmichael C, McHugh NJ (2007) Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. Rheumatology (Oxford) 46:1483–1486CrossRef Gunawardena H, Harris ND, Carmichael C, McHugh NJ (2007) Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. Rheumatology (Oxford) 46:1483–1486CrossRef
188.
Zurück zum Zitat Rossi M, Bazzichi L, Di MC, Franzoni F, Raimo K, Della RA et al (2008) Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. Rheumatology (Oxford) 47:1012–1017CrossRef Rossi M, Bazzichi L, Di MC, Franzoni F, Raimo K, Della RA et al (2008) Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. Rheumatology (Oxford) 47:1012–1017CrossRef
189.
Zurück zum Zitat Furspan PB, Chatterjee S, Freedman RR (2004) Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s disease. Arthritis Rheum 50:1578–1585PubMedCrossRef Furspan PB, Chatterjee S, Freedman RR (2004) Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s disease. Arthritis Rheum 50:1578–1585PubMedCrossRef
190.
Zurück zum Zitat Flavahan NA (2008) Regulation of vascular reactivity in scleroderma: new insights into Raynaud’s phenomenon. Rheum Dis Clin North Am 34:81–87PubMedCrossRef Flavahan NA (2008) Regulation of vascular reactivity in scleroderma: new insights into Raynaud’s phenomenon. Rheum Dis Clin North Am 34:81–87PubMedCrossRef
191.
Zurück zum Zitat Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM et al (2000) Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886–1890PubMedCrossRef Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM et al (2000) Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886–1890PubMedCrossRef
192.
Zurück zum Zitat Generini S, Matucci CM (1999) Raynaud’s phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455:93–100PubMed Generini S, Matucci CM (1999) Raynaud’s phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455:93–100PubMed
193.
Zurück zum Zitat Generini S, Seibold JR, Matucci-Cerinic M (2005) Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am 31:177–1xiPubMedCrossRef Generini S, Seibold JR, Matucci-Cerinic M (2005) Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am 31:177–1xiPubMedCrossRef
194.
Zurück zum Zitat Milner P, Bodin P, Guiducci S, Del RA, Kahaleh MB, Matucci-Cerinic M et al (2004) Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. Clin Exp Rheumatol 22:S24–S27PubMed Milner P, Bodin P, Guiducci S, Del RA, Kahaleh MB, Matucci-Cerinic M et al (2004) Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. Clin Exp Rheumatol 22:S24–S27PubMed
195.
Zurück zum Zitat Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336:1530–1533PubMedCrossRef Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336:1530–1533PubMedCrossRef
196.
Zurück zum Zitat Brain SD, Petty RG, Lewis JD, Williams TJ (1990) Cutaneous blood flow responses in the forearms of Raynaud’s patients induced by local cooling and intradermal injections of CGRP and histamine. Br J Clin Pharmacol 30:853–859PubMed Brain SD, Petty RG, Lewis JD, Williams TJ (1990) Cutaneous blood flow responses in the forearms of Raynaud’s patients induced by local cooling and intradermal injections of CGRP and histamine. Br J Clin Pharmacol 30:853–859PubMed
197.
Zurück zum Zitat Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM (1993) Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 342:80–83PubMedCrossRef Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM (1993) Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 342:80–83PubMedCrossRef
198.
Zurück zum Zitat Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557, A8PubMedCrossRef Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557, A8PubMedCrossRef
199.
Zurück zum Zitat Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT (1998) The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 129:208–211PubMed Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT (1998) The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 129:208–211PubMed
200.
Zurück zum Zitat Wigley FM (2001) Raynaud’s phenomenon is linked to unopposed estrogen replacement therapy in postmenopausal women. Clin Exp Rheumatol 19:10–11PubMed Wigley FM (2001) Raynaud’s phenomenon is linked to unopposed estrogen replacement therapy in postmenopausal women. Clin Exp Rheumatol 19:10–11PubMed
201.
Zurück zum Zitat Mizutani H, Hayashi T, Nouchi N, Inachi S, Suzuki K, Shimizu M (1996) Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 50:293–297PubMed Mizutani H, Hayashi T, Nouchi N, Inachi S, Suzuki K, Shimizu M (1996) Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 50:293–297PubMed
202.
Zurück zum Zitat Salojin KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC et al (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178–185PubMedCrossRef Salojin KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC et al (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178–185PubMedCrossRef
203.
Zurück zum Zitat Kahaleh B (2008) Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 34:57–71PubMedCrossRef Kahaleh B (2008) Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 34:57–71PubMedCrossRef
204.
Zurück zum Zitat Shanahan WR Jr, Korn JH (1982) Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum 25:1391–1395PubMedCrossRef Shanahan WR Jr, Korn JH (1982) Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum 25:1391–1395PubMedCrossRef
205.
Zurück zum Zitat Meyer O, Haim T, Dryll A, Lansaman J, Ryckewaert A (1983) Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 1:29–34PubMed Meyer O, Haim T, Dryll A, Lansaman J, Ryckewaert A (1983) Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 1:29–34PubMed
206.
Zurück zum Zitat Drenk F, Mensing H, Serbin A, Deicher H (1985) Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 5:259–263PubMedCrossRef Drenk F, Mensing H, Serbin A, Deicher H (1985) Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 5:259–263PubMedCrossRef
207.
Zurück zum Zitat Cohen S, Johnson AR, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170–178PubMedCrossRef Cohen S, Johnson AR, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170–178PubMedCrossRef
208.
Zurück zum Zitat Kahaleh MB, LeRoy EC (1983) Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 101:553–560PubMed Kahaleh MB, LeRoy EC (1983) Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 101:553–560PubMed
209.
Zurück zum Zitat Kahaleh MB, Fan PS (1997) Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83:32–40PubMedCrossRef Kahaleh MB, Fan PS (1997) Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83:32–40PubMedCrossRef
210.
Zurück zum Zitat Penning CA, Cunningham J, French MA, Harrison G, Rowell NR, Hughes P (1984) Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 57:548–556PubMed Penning CA, Cunningham J, French MA, Harrison G, Rowell NR, Hughes P (1984) Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 57:548–556PubMed
211.
Zurück zum Zitat Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456PubMed Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456PubMed
212.
Zurück zum Zitat Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A et al (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359–365PubMed Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A et al (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359–365PubMed
213.
Zurück zum Zitat Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111–119PubMedCrossRef Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111–119PubMedCrossRef
214.
Zurück zum Zitat Tan EM, Pearson CM (1972) Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum 15:23–28PubMedCrossRef Tan EM, Pearson CM (1972) Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum 15:23–28PubMedCrossRef
215.
Zurück zum Zitat Hill MB, Phipps JL, Cartwright RJ, Milford WA, Greaves M, Hughes P (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491–497PubMedCrossRef Hill MB, Phipps JL, Cartwright RJ, Milford WA, Greaves M, Hughes P (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491–497PubMedCrossRef
216.
Zurück zum Zitat Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M et al (2000) Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 119:203–209PubMedCrossRef Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M et al (2000) Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 119:203–209PubMedCrossRef
217.
Zurück zum Zitat Negi VS, Tripathy NK, Misra R, Nityanand S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462–466PubMed Negi VS, Tripathy NK, Misra R, Nityanand S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462–466PubMed
218.
Zurück zum Zitat Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N et al (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527–532PubMed Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N et al (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527–532PubMed
219.
Zurück zum Zitat Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA et al (2007) The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127:237–247PubMedCrossRef Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA et al (2007) The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127:237–247PubMedCrossRef
220.
Zurück zum Zitat Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y et al (1999) Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 6:156–160PubMed Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y et al (1999) Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 6:156–160PubMed
221.
Zurück zum Zitat Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC et al (1998) The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101:2029–2035PubMedCrossRef Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC et al (1998) The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101:2029–2035PubMedCrossRef
222.
Zurück zum Zitat Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792PubMedCrossRef Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792PubMedCrossRef
223.
Zurück zum Zitat Nguyen VA, Sgonc R, Dietrich H, Wick G (2000) Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). J Autoimmun 14:143–149PubMedCrossRef Nguyen VA, Sgonc R, Dietrich H, Wick G (2000) Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). J Autoimmun 14:143–149PubMedCrossRef
224.
Zurück zum Zitat Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562PubMedCrossRef Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562PubMedCrossRef
225.
Zurück zum Zitat Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y et al (2005) Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 174:5740–5749PubMed Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y et al (2005) Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 174:5740–5749PubMed
226.
Zurück zum Zitat Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693PubMedCrossRef Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693PubMedCrossRef
227.
Zurück zum Zitat Servettaz A, Tamby MC, Guilpain P, Reinbolt J, Garcia de la Pena-Lefebvre, Allanore Y et al (2006) Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol 120:212–219PubMedCrossRef Servettaz A, Tamby MC, Guilpain P, Reinbolt J, Garcia de la Pena-Lefebvre, Allanore Y et al (2006) Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol 120:212–219PubMedCrossRef
228.
Zurück zum Zitat Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr et al (2003) The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 120:596–606PubMedCrossRef Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr et al (2003) The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 120:596–606PubMedCrossRef
229.
Zurück zum Zitat Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676PubMedCrossRef Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676PubMedCrossRef
230.
Zurück zum Zitat Balada E, Simeon-Aznar CP, Ordi-Ros J, Rosa-Leyva M, Selva-O’Callaghan A, Pardos-Gea J et al (2008) Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67:1027–1029PubMedCrossRef Balada E, Simeon-Aznar CP, Ordi-Ros J, Rosa-Leyva M, Selva-O’Callaghan A, Pardos-Gea J et al (2008) Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67:1027–1029PubMedCrossRef
231.
Zurück zum Zitat Loizos N, Weiner J, Griffin H, Boin F, Hummers LK, Wigley FM et al (2008) Lack of evidence for agonist activity by auto-antibodies to platelet-derived growth factor (PDGF) receptor alpha in systemic sclerosis (scleroderma). Arthritis Rheum 58:S927 Loizos N, Weiner J, Griffin H, Boin F, Hummers LK, Wigley FM et al (2008) Lack of evidence for agonist activity by auto-antibodies to platelet-derived growth factor (PDGF) receptor alpha in systemic sclerosis (scleroderma). Arthritis Rheum 58:S927
232.
Zurück zum Zitat Kahaleh MB, LeRoy EC (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31:195–214PubMedCrossRef Kahaleh MB, LeRoy EC (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31:195–214PubMedCrossRef
233.
Zurück zum Zitat Kahaleh B (2008) The microvascular endothelium in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v14–v15CrossRef Kahaleh B (2008) The microvascular endothelium in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v14–v15CrossRef
234.
Zurück zum Zitat Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183–1186PubMedCrossRef Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183–1186PubMedCrossRef
235.
Zurück zum Zitat Marks RM, Czerniecki M, Andrews BS, Penny R (1988) The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 31:1524–1534PubMedCrossRef Marks RM, Czerniecki M, Andrews BS, Penny R (1988) The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 31:1524–1534PubMedCrossRef
236.
Zurück zum Zitat Majewski S, Blaszczyk M, Jablonska S, Rudnicka L, Wasik M, Skiendzielewska A et al (1990) Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. Rheumatol Int 10:65–70PubMedCrossRef Majewski S, Blaszczyk M, Jablonska S, Rudnicka L, Wasik M, Skiendzielewska A et al (1990) Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. Rheumatol Int 10:65–70PubMedCrossRef
237.
Zurück zum Zitat Rudnicka L, Majewski S, Blaszczyk M, Skiendzielewska A, Makiela B, Skopinska M et al (1992) Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 35:771–775PubMedCrossRef Rudnicka L, Majewski S, Blaszczyk M, Skiendzielewska A, Makiela B, Skopinska M et al (1992) Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 35:771–775PubMedCrossRef
238.
Zurück zum Zitat Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31:514–519PubMed Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31:514–519PubMed
239.
Zurück zum Zitat Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS (1994) Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 70:830–835PubMed Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS (1994) Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 70:830–835PubMed
240.
Zurück zum Zitat Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M et al (2000) Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 27:402–404PubMed Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M et al (2000) Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 27:402–404PubMed
241.
Zurück zum Zitat Helmbold P, Fiedler E, Fischer M, Marsch WC (2004) Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31:431–440PubMedCrossRef Helmbold P, Fiedler E, Fischer M, Marsch WC (2004) Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31:431–440PubMedCrossRef
242.
Zurück zum Zitat Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941PubMedCrossRef Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941PubMedCrossRef
243.
Zurück zum Zitat Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123PubMedCrossRef Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123PubMedCrossRef
244.
Zurück zum Zitat Postlethwaite AE, Shigemitsu H, Kanangat S (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16:733–738PubMedCrossRef Postlethwaite AE, Shigemitsu H, Kanangat S (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16:733–738PubMedCrossRef
245.
Zurück zum Zitat Denton CP, Xu S, Welsh KI, Pearson JD, Black CM (1996) Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. J Rheumatol 23:633–638PubMed Denton CP, Xu S, Welsh KI, Pearson JD, Black CM (1996) Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. J Rheumatol 23:633–638PubMed
246.
Zurück zum Zitat Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD (1998) Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 114:293–300PubMedCrossRef Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD (1998) Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 114:293–300PubMedCrossRef
247.
Zurück zum Zitat Gruschwitz MS, Vieth G (1997) Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 40:540–550PubMedCrossRef Gruschwitz MS, Vieth G (1997) Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 40:540–550PubMedCrossRef
248.
Zurück zum Zitat Faller DV (1999) Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 26:74–84PubMedCrossRef Faller DV (1999) Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 26:74–84PubMedCrossRef
249.
Zurück zum Zitat Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322PubMedCrossRef Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322PubMedCrossRef
250.
Zurück zum Zitat Hong KH, Yoo SA, Kang SS, Choi JJ, Kim WU, Cho CS (2006) Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 146:362–370PubMedCrossRef Hong KH, Yoo SA, Kang SS, Choi JJ, Kim WU, Cho CS (2006) Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 146:362–370PubMedCrossRef
251.
Zurück zum Zitat Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV (2008) Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol 30:329–337PubMedCrossRef Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV (2008) Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol 30:329–337PubMedCrossRef
252.
Zurück zum Zitat Klareskog L, Gustafsson R, Scheynius A, Hallgren R (1990) Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33:1534–1541PubMedCrossRef Klareskog L, Gustafsson R, Scheynius A, Hallgren R (1990) Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33:1534–1541PubMedCrossRef
253.
Zurück zum Zitat Zheng XY, Zhang JZ, Tu P, Ma SQ (1998) Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 18:90–97PubMedCrossRef Zheng XY, Zhang JZ, Tu P, Ma SQ (1998) Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 18:90–97PubMedCrossRef
254.
Zurück zum Zitat Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79PubMedCrossRef Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79PubMedCrossRef
255.
Zurück zum Zitat Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653PubMed Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653PubMed
256.
Zurück zum Zitat Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed
257.
Zurück zum Zitat Blake DR, Winyard P, Scott DG, Brailsford S, Blann A, Lunec J (1985) Endothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteins. Ann Rheum Dis 44:176–182PubMedCrossRef Blake DR, Winyard P, Scott DG, Brailsford S, Blann A, Lunec J (1985) Endothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteins. Ann Rheum Dis 44:176–182PubMedCrossRef
258.
Zurück zum Zitat Tikly M, Channa K, Theodorou P, Gulumian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324PubMedCrossRef Tikly M, Channa K, Theodorou P, Gulumian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324PubMedCrossRef
259.
Zurück zum Zitat Whittaker R, Barnett A, Ryan P (1993) Antiphospholipid syndrome in scleroderma. J Rheumatol 20:1598–1600PubMed Whittaker R, Barnett A, Ryan P (1993) Antiphospholipid syndrome in scleroderma. J Rheumatol 20:1598–1600PubMed
260.
Zurück zum Zitat Chun WH, Bang D, Lee SK (1996) Antiphospholipid syndrome associated with progressive systemic sclerosis. J Dermatol 23:347–351PubMed Chun WH, Bang D, Lee SK (1996) Antiphospholipid syndrome associated with progressive systemic sclerosis. J Dermatol 23:347–351PubMed
261.
Zurück zum Zitat Zandman-Goddard G, Tweezer-Zaks N, Shalev T, Levy Y, Ehrenfeld M, Langevitz P (2007) A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome—a case series. Ann N Y Acad Sci 1108:497–504PubMedCrossRef Zandman-Goddard G, Tweezer-Zaks N, Shalev T, Levy Y, Ehrenfeld M, Langevitz P (2007) A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome—a case series. Ann N Y Acad Sci 1108:497–504PubMedCrossRef
262.
Zurück zum Zitat Bamberga P, Asero R, Vismara A, Brucato A, Riboldi P, Meroni PL (1987) Anti-cardiolipin antibodies in progressive systemic sclerosis (PSS). Clin Exp Rheumatol 5:387–388PubMed Bamberga P, Asero R, Vismara A, Brucato A, Riboldi P, Meroni PL (1987) Anti-cardiolipin antibodies in progressive systemic sclerosis (PSS). Clin Exp Rheumatol 5:387–388PubMed
263.
Zurück zum Zitat Katayama I, Otoyama K, Kondo S, Nishioka K, Nishiyama S (1990) Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol 23:198–201PubMedCrossRef Katayama I, Otoyama K, Kondo S, Nishioka K, Nishiyama S (1990) Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol 23:198–201PubMedCrossRef
264.
Zurück zum Zitat Speranskii AI, Riazantseva TA, Guseva NG, Melkumova KL, Ivanova SM (1990) [Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma]. Revmatologiia (Mosk) 3:11–14 Speranskii AI, Riazantseva TA, Guseva NG, Melkumova KL, Ivanova SM (1990) [Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma]. Revmatologiia (Mosk) 3:11–14
265.
Zurück zum Zitat Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G (1995) Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 20:1–7PubMedCrossRef Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G (1995) Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 20:1–7PubMedCrossRef
266.
Zurück zum Zitat Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP (1996) The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101:576–583PubMedCrossRef Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP (1996) The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101:576–583PubMedCrossRef
267.
Zurück zum Zitat Sulik A, Kowal-Bielecka O, Domyslawska I, Chwiecko J, Sierakowski S (2005) The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis—preliminary report. Rocz Akad Med Bialymst 50 Suppl 1:228–231 Sulik A, Kowal-Bielecka O, Domyslawska I, Chwiecko J, Sierakowski S (2005) The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis—preliminary report. Rocz Akad Med Bialymst 50 Suppl 1:228–231
268.
Zurück zum Zitat Pope JE, Thompson A (2000) The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 27:1450–1452PubMed Pope JE, Thompson A (2000) The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 27:1450–1452PubMed
269.
Zurück zum Zitat Marai I, Gilburd B, Blank M, Shoenfeld Y (2003) Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 12:57–62PubMed Marai I, Gilburd B, Blank M, Shoenfeld Y (2003) Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 12:57–62PubMed
270.
Zurück zum Zitat Enzenauer RJ, Collier DH, Lopez LR (2006) Anticardiolipin antibodies in scleroderma. J Clin Rheumatol 12:324–326PubMedCrossRef Enzenauer RJ, Collier DH, Lopez LR (2006) Anticardiolipin antibodies in scleroderma. J Clin Rheumatol 12:324–326PubMedCrossRef
271.
Zurück zum Zitat Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR et al (1988) Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 73:456–460PubMed Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR et al (1988) Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 73:456–460PubMed
272.
Zurück zum Zitat Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23:199–204PubMed Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23:199–204PubMed
273.
Zurück zum Zitat Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326PubMedCrossRef Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326PubMedCrossRef
274.
Zurück zum Zitat Marie I, Jouen F, Hellot MF, Levesque H (2008) Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158:141–144PubMed Marie I, Jouen F, Hellot MF, Levesque H (2008) Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158:141–144PubMed
275.
Zurück zum Zitat Boin F, Johnson E, Rosen A, Wigley F, Casciola-Rosen L (2008) Anti-beta2 Glycoprotein I antibodies are independently associated with macrovascular disease and mortality in Scleroderma Patients. Arthritis Rheum 58:S946–S947CrossRef Boin F, Johnson E, Rosen A, Wigley F, Casciola-Rosen L (2008) Anti-beta2 Glycoprotein I antibodies are independently associated with macrovascular disease and mortality in Scleroderma Patients. Arthritis Rheum 58:S946–S947CrossRef
276.
Zurück zum Zitat Harigai M, Hara M, Nakazawa S, Fukasawa C, Ohta S, Sugiura T et al (1999) Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. J Rheumatol 26:1035–1043PubMed Harigai M, Hara M, Nakazawa S, Fukasawa C, Ohta S, Sugiura T et al (1999) Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. J Rheumatol 26:1035–1043PubMed
277.
Zurück zum Zitat Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E et al (1990) Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol 29:644–648PubMedCrossRef Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E et al (1990) Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol 29:644–648PubMedCrossRef
278.
Zurück zum Zitat Munkvad S, Gram J, Jespersen J (1989) Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Scand J Rheumatol 18:277–282PubMedCrossRef Munkvad S, Gram J, Jespersen J (1989) Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Scand J Rheumatol 18:277–282PubMedCrossRef
279.
Zurück zum Zitat Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295PubMedCrossRef Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295PubMedCrossRef
280.
Zurück zum Zitat Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L et al (1997) The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 36:1045–1050PubMedCrossRef Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L et al (1997) The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 36:1045–1050PubMedCrossRef
281.
Zurück zum Zitat Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847PubMedCrossRef Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847PubMedCrossRef
282.
Zurück zum Zitat Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A (2005) Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 7:R93–100PubMedCrossRef Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A (2005) Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 7:R93–100PubMedCrossRef
283.
Zurück zum Zitat Sunkel CE, Fau dC-J, Cillero FJ, Priego JG, Ortega MP (1988) Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J Med Chem 31:1886–1890PubMedCrossRef Sunkel CE, Fau dC-J, Cillero FJ, Priego JG, Ortega MP (1988) Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J Med Chem 31:1886–1890PubMedCrossRef
284.
Zurück zum Zitat Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85:2093–2102PubMedCrossRef Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85:2093–2102PubMedCrossRef
285.
Zurück zum Zitat Morris JL, Gibbins IL, Kadowitz PJ, Herzog H, Kreulen DL, Toda N et al (1995) Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Can J Physiol Pharmacol 73:521–532PubMed Morris JL, Gibbins IL, Kadowitz PJ, Herzog H, Kreulen DL, Toda N et al (1995) Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Can J Physiol Pharmacol 73:521–532PubMed
286.
Zurück zum Zitat Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev:CD000956 Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev:CD000956
287.
Zurück zum Zitat Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278:H1075–H1083PubMed Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278:H1075–H1083PubMed
288.
Zurück zum Zitat Bailey SR, Mitra S, Flavahan S, Flavahan NA (2005) Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 289:H243–H250PubMedCrossRef Bailey SR, Mitra S, Flavahan S, Flavahan NA (2005) Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 289:H243–H250PubMedCrossRef
289.
Zurück zum Zitat Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA (2004) Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 94:1367–1374PubMedCrossRef Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA (2004) Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 94:1367–1374PubMedCrossRef
290.
Zurück zum Zitat Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J et al (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58:2553–2564PubMedCrossRef Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J et al (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58:2553–2564PubMedCrossRef
291.
Zurück zum Zitat Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H et al (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994–4001PubMedCrossRef Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H et al (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994–4001PubMedCrossRef
292.
Zurück zum Zitat Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ et al (1989) International study of ketanserin in Raynaud’s phenomenon. Am J Med 87:264–268PubMedCrossRef Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ et al (1989) International study of ketanserin in Raynaud’s phenomenon. Am J Med 87:264–268PubMedCrossRef
293.
Zurück zum Zitat Seibold JR, Jageneau AH (1984) Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum 27:139–146PubMedCrossRef Seibold JR, Jageneau AH (1984) Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum 27:139–146PubMedCrossRef
294.
Zurück zum Zitat Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud’s phenomenon in Progressive Systemic Sclerosis. Cochrane Database Syst Rev 2:CD000954PubMed Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud’s phenomenon in Progressive Systemic Sclerosis. Cochrane Database Syst Rev 2:CD000954PubMed
295.
Zurück zum Zitat Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2003) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 42:601–602CrossRef Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2003) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 42:601–602CrossRef
296.
Zurück zum Zitat Giannattasio C, Pozzi M, Gardinali M, Montemerlo E, Citterio F, Maestroni S et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797PubMedCrossRef Giannattasio C, Pozzi M, Gardinali M, Montemerlo E, Citterio F, Maestroni S et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797PubMedCrossRef
297.
Zurück zum Zitat Winkelmann RK, Goldyne ME, Linscheid RL (1976) Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 95:51–56PubMedCrossRef Winkelmann RK, Goldyne ME, Linscheid RL (1976) Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 95:51–56PubMedCrossRef
298.
Zurück zum Zitat Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508PubMed Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508PubMed
299.
Zurück zum Zitat Chung L, Fiorentino D (2006) A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 54:880–882PubMedCrossRef Chung L, Fiorentino D (2006) A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 54:880–882PubMedCrossRef
300.
Zurück zum Zitat Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206PubMed Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206PubMed
301.
Zurück zum Zitat Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O et al (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43:56S–61SPubMedCrossRef Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O et al (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43:56S–61SPubMedCrossRef
302.
Zurück zum Zitat Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434PubMed Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434PubMed
303.
Zurück zum Zitat Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502PubMedCrossRef Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502PubMedCrossRef
304.
Zurück zum Zitat Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329PubMedCrossRef Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329PubMedCrossRef
305.
Zurück zum Zitat Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241–250PubMed Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241–250PubMed
306.
Zurück zum Zitat Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M et al (2007) Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 71:1829–1831PubMedCrossRef Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M et al (2007) Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 71:1829–1831PubMedCrossRef
307.
Zurück zum Zitat Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125PubMedCrossRef Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125PubMedCrossRef
308.
Zurück zum Zitat Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123PubMedCrossRef Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123PubMedCrossRef
309.
Zurück zum Zitat Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMedCrossRef Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMedCrossRef
310.
Zurück zum Zitat Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ (2007) Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26:63–69PubMedCrossRef Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ (2007) Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26:63–69PubMedCrossRef
311.
Zurück zum Zitat Cheng JW (2008) Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 30:825–833PubMedCrossRef Cheng JW (2008) Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 30:825–833PubMedCrossRef
312.
Zurück zum Zitat Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985–1993PubMedCrossRef Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985–1993PubMedCrossRef
313.
Zurück zum Zitat Jain M, Varga J (2006) Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 7:1487–1501PubMedCrossRef Jain M, Varga J (2006) Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 7:1487–1501PubMedCrossRef
314.
Zurück zum Zitat Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R et al (2007) Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 34:1712–1717PubMed Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R et al (2007) Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 34:1712–1717PubMed
315.
Zurück zum Zitat Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N et al (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–2422PubMed Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N et al (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–2422PubMed
316.
Zurück zum Zitat Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK et al (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402PubMedCrossRef Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK et al (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402PubMedCrossRef
317.
Zurück zum Zitat Fries R, Shariat K, von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed Fries R, Shariat K, von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed
318.
Zurück zum Zitat Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 41:324–328CrossRef Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 41:324–328CrossRef
319.
Zurück zum Zitat Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34:636–641PubMedCrossRef Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34:636–641PubMedCrossRef
320.
Zurück zum Zitat Chung L, Baron M, Collier DH, Csuka ME, Fiorentino D, Gruber B et al (2007) A multi-center placebo-controlled “In-Life” study of MQX-503 in patients with Raynaud phenomenon. Arthritis Rheum 56:S824 Chung L, Baron M, Collier DH, Csuka ME, Fiorentino D, Gruber B et al (2007) A multi-center placebo-controlled “In-Life” study of MQX-503 in patients with Raynaud phenomenon. Arthritis Rheum 56:S824
321.
Zurück zum Zitat Fleming JN, Schwartz SM (2008) The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 34:41–55PubMedCrossRef Fleming JN, Schwartz SM (2008) The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 34:41–55PubMedCrossRef
322.
Zurück zum Zitat Agewall S, Hernberg A (2006) Atorvastatin normalizes endothelial function in healthy smokers. Clin Sci (Lond) 111:87–91 Agewall S, Hernberg A (2006) Atorvastatin normalizes endothelial function in healthy smokers. Clin Sci (Lond) 111:87–91
323.
Zurück zum Zitat Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46:1560–1565CrossRef Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46:1560–1565CrossRef
324.
Zurück zum Zitat Iida K, Goland S, Akima T, Luo H, Birnbaum Y, Siegel RJ (2007) Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. Am J Cardiol 100:881–884PubMedCrossRef Iida K, Goland S, Akima T, Luo H, Birnbaum Y, Siegel RJ (2007) Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. Am J Cardiol 100:881–884PubMedCrossRef
325.
Zurück zum Zitat Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E et al (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646–2655PubMedCrossRef Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E et al (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646–2655PubMedCrossRef
326.
Zurück zum Zitat Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316PubMed Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316PubMed
327.
Zurück zum Zitat Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691–2694PubMedCrossRef Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691–2694PubMedCrossRef
328.
Zurück zum Zitat Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412–1413PubMedCrossRef Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412–1413PubMedCrossRef
329.
Zurück zum Zitat van der MJ, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud’s phenomenon. Vasa Suppl 18:71–75 van der MJ, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud’s phenomenon. Vasa Suppl 18:71–75
330.
Zurück zum Zitat Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY et al (1984) Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27:1137–1143PubMedCrossRef Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY et al (1984) Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27:1137–1143PubMedCrossRef
331.
Zurück zum Zitat Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol 18:499–502PubMed Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol 18:499–502PubMed
332.
Zurück zum Zitat Goldberg J, Dlesk A (1986) Successful treatment of Raynaud’s phenomenon with pentoxifylline. Arthritis Rheum 29:1055–1056PubMedCrossRef Goldberg J, Dlesk A (1986) Successful treatment of Raynaud’s phenomenon with pentoxifylline. Arthritis Rheum 29:1055–1056PubMedCrossRef
333.
Zurück zum Zitat Goodfield MJ, Rowell NR (1989) Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline. Clin Exp Dermatol 14:161–162PubMedCrossRef Goodfield MJ, Rowell NR (1989) Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline. Clin Exp Dermatol 14:161–162PubMedCrossRef
334.
Zurück zum Zitat Dean SM, Satiani B (2001) Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 6:245–248PubMedCrossRef Dean SM, Satiani B (2001) Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 6:245–248PubMedCrossRef
335.
Zurück zum Zitat Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford) 38:309–315CrossRef Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford) 38:309–315CrossRef
336.
Zurück zum Zitat Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257–2262PubMed Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257–2262PubMed
337.
Zurück zum Zitat Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed
338.
Zurück zum Zitat Sycha T, Graninger M, Auff E, Schnider P (2004) Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest 34:312–313PubMedCrossRef Sycha T, Graninger M, Auff E, Schnider P (2004) Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest 34:312–313PubMedCrossRef
Metadaten
Titel
Vascular Disease in Scleroderma
verfasst von
Fredrick M. Wigley
Publikationsdatum
01.06.2009
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2-3/2009
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-008-8106-x

Weitere Artikel der Ausgabe 2-3/2009

Clinical Reviews in Allergy & Immunology 2-3/2009 Zur Ausgabe

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.